Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

Breadcrumb trail:

Rheumatology Board

Expand All | Collapse All

Marcy B. Bolster, MD, Chair

Marcy B. Bolster, MDDr. Bolster is an Associate Professor of Medicine at Harvard Medical School. She is the Director of the rheumatology fellowship training program in the Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital (MGH). She is a board certified rheumatologist.

Prior to her position at MGH, she was a Professor of Medicine, Division of Rheumatology, at the Medical University of South Carolina (MUSC), where she was on the faculty from 1993-2012. She also served as the Director of the rheumatology fellowship training program, the Medical Director of the Center for Osteoporosis and Bone Health and the Medical Director of the Musculoskeletal Institute at MUSC.

She is a fellow of the American College of Physicians and of the American College of Rheumatology (ACR), a member of the International Society for Clinical Densitometry and a member of the American Society for Bone Mineral Research. She is Chair, ACR Committee on Training and Workforce (COTW). She has served as co-leader for the ACR in the ACGME Next Accreditation System. She is a member of both the ACR and the Rheumatology Research Foundation Boards of Directors. She has served on the American Board of Internal Medicine (ABIM) Rheumatology Board and is currently its Chair. She is also the Chair of the ABIM Rheumatology Board Exam Committee, serves as a member of the ABIM Council and is the Chair of the ABIM Exam Chairs Committee. She is a member of the MGH Department of Medicine Education Council and Innovation in Education Committee. She previously served as the co-Chairperson for the ACR Rheumatology In-Training Examination and on the ACR COTW, chairing the Sub-Committee on Resident Education, spearheading the development of “Rheum2Learn,” an online internal medicine resident education tool for rheumatology.

She obtained a bachelor of arts degree in chemistry and her medical degree from Duke University. She trained in internal medicine at the Eastern Virginia Graduate School of Medicine and obtained rheumatology training at MUSC.

As of January 2017, Dr. Bolster reported the following external relationships:

Clinical research, with funding for clinical trial expenses, clinical research staff and salary support, paid to Brigham and Women's Hospital and Massachusetts General Hospital, from the following company:

  • Eli Lilly & Co., to study the use of teriparatide in patients with rheumatoid arthritis to determine if it might help improve erosions.

Work funded by educational grants from industry, paid directly to Massachusetts General Hospital Rheumatology, from the following companies:

  • AbbVie, providing partial salary support for a rheumatology fellow; funding is used solely for a fellow's salary support.
  • Amgen, providing partial salary support for a rheumatology fellow through the Rheumatology Research Foundation; funding is used solely for a fellow's salary support.

Work as an author or editor for following companies, with compensation as listed below:

  • Elsevier, receiving compensation as an editor for a volume of Rheumatic Disease Clinics of North America: Corticosteroids.
  • Merck Manual, receiving compensation as an author.

Susan K. Chrostowski, DNP, APRN, ANP-C

Dr. Susan Chrostowski is an Assistant Clinical Professor at Texas Woman's University in Dallas, Texas where she teaches in the graduate nursing program. Dr. Chrostowski earned her Bachelor of Science in nursing degree at Texas Woman's University in Denton, Texas. She went on to earn a Master of Science degree in nursing, and Doctor of Nursing Practice degree at Texas Woman's University in Dallas, Texas. For her doctoral program, she conducted a clinical research study on assessment instruments on fibromyalgia disease activity and presented those results at the American College of Rheumatology Annual Scientific Meeting in San Francisco, CA in 2015.

Dr. Chrostowski is certified as an Adult Health nurse practitioner through the American Academy of Nurse Practitioners certification board and has been practicing exclusively in rheumatology since 2005. Dr. Chrostowski serves as a member of the American Board of Internal Medicine Rheumatology Board. She has served on several national committees with the Association of Rheumatology Professionals organization. In addition to podium and poster presentations at local and national conferences on rheumatology and geriatric nursing practice, Dr. Chrostowski has published several articles related to rheumatology and nursing practice issues.

As of November 2018, Dr. Chrostowski reported no ongoing external relationships:

Atulya A. Deodhar, MD

Atulya A. Deodhar, MDDr. Deodhar, a board certified internist and rheumatologist, is Professor of Medicine and Medical Director of rheumatology clinics at the Division of Arthritis & Rheumatic Diseases in Oregon Health & Science University, Portland. He is a fellow of the American College of Rheumatology (ACR) and the American College of Physicians.

Dr. Deodhar is the Chairman of SPARTAN (Spondyloarthritis Research and Treatment Network), an organization of North American rheumatologists dedicated to education and research in the field of axial spondyloarthritis. He serves on the ACR's treatment guidelines subcommittee and has served in the past as a member and Vice Chair of the Annual Meeting Planning Committee and as a member of the Peripheral MRI Task Force. Dr. Deodhar also served on the Association of Rheumatology Health Professionals (ARHP) nominating committee. Additionally, he serves as a member of the American Board of Internal Medicine Rheumatology Board.

Dr. Deodhar is a reviewer for Arthritis & Rheumatology, Annals of the Rheumatic Diseases and Annals of Internal Medicine, among several other journals. His research interests are axial spondyloarthritis and psoriatic arthritis. He has authored three books, more than 100 peer-reviewed articles, several book chapters, and editorials. Dr. Deodhar has been a principal or co-investigator in more than 100 clinical trials, mainly focused on therapies for ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis.

He completed his fellowship in rheumatology at Oregon Health & Science University, and before that, a research fellowship in rheumatology at the Royal Cornwall Hospital, Truro, England. He completed his residency in internal medicine and geriatrics at the Royal Cornwall Hospital, Truro, as well as in the Sassoon General Hospital and King Edward Memorial Hospital, Pune, India. Dr. Deodhar received his bachelor's degree in medicine and surgery and his medical degree from the University of Pune, India, and his membership of the Royal College of Physicians, London, England.

As of March 2019, Dr. Deodhar reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to Oregon Health and Science University, from the following companies:

  • * Eli Lilly & Co., funding work as Principal Investigator for studies of ixekizumab in the treatment of axial spondyloarthritis and psoriatic arthritis.
  • * Novartis, funding work as Principal Investigator for trials of secukinumab in the treatment of non-radiographic axial spondylarthritis and psoriatic arthritis.
  • * Pfizer, funding work as Principal Investigator for a trial of tofacoitinibin the treatment of axial spondyloarthritis.
  • UCB, funding work as Principal Investigator for trials of certolizumab and bimekizumab in the treatment of non-radiographic axial spondyloarthritis.

Investigators' meetings for the following companies, with compensation as listed:

  • Eli Lilly and Company, meeting to consult on research studies of ixekizumab and baricitinib in axial spondyloarthritis, receiving honoraria.
  • Janssen, clinical research protocol discussion meeting regarding three different trials - in ankylosing spondylitis, and non-radiographic axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • Novartis, research meeting related to trials of secukinumab in non-radiographic axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • UCB, teleconferences regarding the study of non-radiographic axial spondyloarthritis, receiving honoraria.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • AbbVie, advising on treatment of axial spondyloarthritis with upadacitinib, receiving reimbursement for travel expenses and honoraria.
  • Boehringer Ingelheim, advising on treatment of axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • Bristol-Myers Squibb, advising on treatment of axial spondyloarthritis and non-radiographic axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • Eli Lilly and Company, to discuss results of research studies of ixekizumab in psoriatic arthritis, receiving reimbursement for travel expenses and honoraria.
  • GlaxoSmithKline, advising on treatment of axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • Novartis, to discuss the clinical trial design for secukinumab in the treatment of non-radiographic axial spondyloarthritis, and to discuss the future of targeted therapies, receiving reimbursement for travel expenses and honoraria.
  • Pfizer, to discuss the ongoing trial of etanercept in non-radiographic axial spondyloarthritis,, receiving reimbursement for travel expenses and honoraria.

UCB, to discuss the drugs certolizumab and bimekizumab and the future landscape of treatments for axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation as listed:

  • Eli Lilly and Company, providing advice on a clinical trial protocol for the use of ixekizumab in ankylosing spondylitis, receiving honoraria.
  • Novartis, advising on a study on the axial spondyloarthritis patient journey, receiving reimbursement for travel expenses and honoraria.

Industry-supported continuing medical education supported by the following companies, with compensation for travel expenses and honoraria:

  • Dr. Deodhar also serves as faculty for educational symposia at PANLAR Congress, EULAR meeting, and Brazilian spondyloarthritis interest group, receiving reimbursement for travel expenses and honoraria from Novartis.
  • Dr. Deodhar also gives lectures at educational events in Brazil, receiving reimbursement for travel expenses and honoraria from Janssen.
  • * Dr. Deodhar also serves as faculty for educational symposia on axial spondyloarthritis and psoriatic arthritis, with continuing medical education credits provided by Oregon Health & Science University and with the symposia organized by SPARTAN and GRAPPA.

Dr. Deodhar serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Rheumatology, Member of Treatment Guidelines Subcommittee, and Core Member, Treatment Guidelines for Axial Spondyloarthritis, receiving reimbursement for travel expenses.

Dr. Deodhar also reported receiving honoraria and reimbursement for travel expenses from Janssen, Novartis, and Pfizer for preceptorship for medical science liasons on axial spondyloarthritis and psoriatic arthritis organized by NW Rheumatology and Osteoporosis Institute, Seattle.

Carlos M. Gadea MD

Carlos M. Gadea MDDr. Gadea is a rheumatologist at the University of Alabama at Birmingham (UAB) Medicine Multispecialty Clinic at Baptist Medical Center South in Montgomery, Alabama. As a clinical instructor, he works with internal medicine residents from the UAB-Montgomery Internal Medicine residency program on their rheumatology elective rotation. He is board certified in both Internal Medicine and Rheumatology.

Prior to his work at UAB, Dr. Gadea worked in a small private rheumatology practice in Seaford, Delaware, with two other rheumatologists. Before that, Dr. Gadea practiced in Pittsburgh, Pennsylvania, at the University of Pittsburgh Medical Center (UPMC). As a Clinical Instructor for the UPMC Division of Rheumatology, he worked as a rheumatologist in one of the division’s satellite rheumatology clinics caring for patients, and providing consultation at St. Clair Hospital and UPMC Mercy, where he also worked with internal medicine residents. After fellowship training, he practiced with a private rheumatology group with four other rheumatologists in Virginia Beach, Virginia.

Dr. Gadea is a member of the American Board of Internal Medicine Rheumatology Board.

Dr. Gadea received his bachelor’s degree in biological sciences from Florida International University. He earned his medical degree from Universidad de Ciencias Medicas de Centro America in San Jose, Costa Rica. He completed his internal medicine residency training with the University of Connecticut Primary Care Internal Medicine program in Farmington, Connecticut, and his rheumatology fellowship at the University of Kentucky in Lexington, Kentucky.

As of January 2018, Dr. Gadea reported no external relationships.

Kristine M. Lohr, MD

Kristine M. Lohr, MDDr. Lohr, board certified in Rheumatology, is Professor of Medicine, Director of the Rheumatology Fellowship Program, and Interim Chief of the Division of Rheumatology in the Department of Medicine at the University of Kentucky in Lexington, Kentucky.

Previously, as a faculty member of The University of Tennessee Health Science Center (UTHSC) College of Medicine, she served as Director of two courses (Pathophysiology and Introduction to Clinical Skills) before becoming Associate Dean for Outcomes Research and Improvement. As Associate Dean, she developed and co-directed the Patient Safety/Quality Improvement Clerkship. She began her academic career as an Assistant Professor of Medicine at The Medical College of Wisconsin.

Dr. Lohr served as co-Chair for the American College of Rheumatology (ACR) Annual Review Course. She is currently a member of the ACR Committee on Workforce and Training and the ACR Annual Meeting Planning Committee. She is also a Board Member of Rheumatology Network and represents the ACR as a Board Member of the United States Bone and Joint Initiative. Dr. Lohr received the ACR Clinician Scholar Educator Award while at UTHSC, and was a fellow of the Hedwig van Ameringen Executive Leadership in Academic Medicine Program at Allegheny University for the Health Sciences (now Drexel University College of Medicine). She is currently a member of the American Board of Internal Medicine (ABIM) Rheumatology Board and was formerly a member of the ABIM Rheumatology Board Exam Committee. Her academic career has centered on undergraduate and graduate medical education.

Dr. Lohr earned her medical degree at the University of Rochester School of Medicine and Dentistry. She did her residency in the Department of Medicine at The Ohio State University Hospital and fellowship training in rheumatology at Duke University Medical Center.

As of January 2017, Dr. Lohr reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Kentucky, from the following company:

  • Takeda, for a study evaluating the cardiovascular safety and efficacy of febuxostat and allopurinol in subjects with cardiovascular comorbidities, hyperuricemia and gout.

Dr. Lohr serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Rheumatology, Member of the Annual Meeting Planning Committee, receiving reimbursement for travel expenses and registration for the annual meeting; Member of the Workforce and Training Committee, receiving reimbursement for travel expenses; Member of Audiovisual Aids Subcommittee, receiving reimbursement for travel expenses.
  • United States Bone and Joint Initiative, serving as the American College of Rheumatology representative to their Board of Directors, receiving reimbursement for travel expenses.

Dr. Lohr serves on the Rheumatology Network Board, and as a member of the Editorial Board, with honoraria paid to the University of Kentucky.

Maryah Mansoor, MD

Dr. Mansoor, a board certified internist and rheumatologist, practices at Christiana Care Hospital Delaware. She is also Clinical Assistant Professor of Medicine at Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia, PA.

Dr. Mansoor is a member of the American Board of Internal Medicine Rheumatology Board. She also volunteered for standard setting process for ABIM Rheumatology Certification exam. She is also a Board Member of the Arthritis Foundation Delaware. Dr. Mansoor is involved in the teaching of internal medicine residents at Christiana Care Hospital.

Dr. Mansoor earned her medical degree as a class valedictorian from Aga Khan Medical University in Karachi, Pakistan. She completed her residency in internal medicine at Staten Island University Hospital (North well Health) and fellowship in rheumatology at Sidney Kimmel Medical College at Thomas Jefferson University.

As of November 2018, Dr. Mansoor reported no ongoing external relationships:

Philip Seo, MD

Dr. Seo is the Director of the Johns Hopkins Vasculitis Center and Director of the Johns Hopkins Rheumatology Fellowship Training Program. He is board certified in both internal medicine and rheumatology. Dr. Seo received a Bachelor of Arts degree in biochemical sciences from Harvard College, a medical degree from Columbia University, and a Master in Health Science degree from the Johns Hopkins Bloomberg School of Public Health. He completed his training in both internal medicine and rheumatology at the Johns Hopkins Hospital, where he also served as an Assistant Chief of Service (Chief Resident).

Dr. Seo has served the American College of Rheumatology (ACR) in a variety of capacities, including as a member of the Committee on Training and Workforce, the Annual Meeting Planning Committee, and the In-Training Examination Taskforce. He has served as a Co-Chair of both the ACR In-Training Examination Taskforce and Annual Scientific Meeting Review Course.

He is now serving the ACR as a Co-Chair of the non-ANCA Vasculitis Abstract Selection Committee for the Annual Scientific Meeting. Dr. Seo serves as a member of the American Board of Internal Medicine Rheumatology Board; he is also the Medical Editor of the Rheumatologist, an official publication of the ACR. He is a recipient of a Clinician Scholar Educator Award from the Rheumatology Research Foundation. Dr. Seo is a Medical Consultant for the Vasculitis Foundation, the largest patient support group for the systemic vasculitides in the United States.

As of November 2018, Dr. Seo reported the following ongoing external relationships:

Service on data and safety monitoring boards for the following companies, with honoraria:

  • Celgene, for a clinical trial examining the use of apremilast in a pediatric population for the treatment of psoriasis.

Work as an author or editor for following companies, with compensation as listed:

  • American College of Rheumatology, receiving compensation as a medical editor for The Rheumatologist.

Daniel McGowan, MD

In nearly 50 years in the health care system Daniel McGowan has managed many elements of that system. He has directed health system planning and regulation for the State of Wisconsin, Long Island and NY City. He has served as Vice-President of Long Island Jewish Medical Center, Executive Director of Catholic Charities health and human services on Long Island and as President and Chief Operating Officer of both the Health Insurance Plan of Greater NY and Emblem Health Services Corporation, the largest Medicare Advantage, Medicaid and HMO in New York.

Mr. McGowan currently chairs the Primary Care Development Corporation and Hygea Health Holdings Corporation, and is past chair of National Medical Fellowships and the National Board of the Arthritis Foundation. He serves as a member of the American Board of Internal Medicine Rheumatology Board, and was the Arthritis Foundation's representative to the Board of the American College of Rheumatology. He also served as Trustee of Molloy College and the Health Industry Forum of Brandeis University. Frequently teaching the US Health Care System, Health Planning and Regulation at both undergraduate and graduate levels, he has held faculty posts at Governors State University in Illinois, the University of Wisconsin and Long Island University.

Now retired, Mr. McGowan resides in Palm Coast, Florida with his wife, Deborah. He travels frequently to several boards on which he serves and to visit his 2 daughters Erin and Meghan and their families in Green Bay, WI and Minneapolis, MN respectively.

Mr. McGowan holds many honors from various organizations, and is a Certified Rehabilitation Counselor, a Rockefeller Fellow and a Licensed Captain by the US Coast Guard. He enjoys boating and biking with family and friends.